Astrazeneca Ab

Astra Aktiebolag

Helene Depui

Per Johan Lundberg

Agneta Hallgren

Adam Rosinski

An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.

Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID

An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antacid agents or an alginate in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer and an optional separating layer in between the proton pump inhibitor and the enteric coating. The fixed formulation is in the form of multilayered tablets, sachets or multiple unit tableted dosage forms. The multiple unit dosage form is most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with dyspepsia such as heartburn.

Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate

Oral pharmaceutical dosage form

Oral pharmaceutical dosage forms comprising a proton pump inhibitor and

Growing community of inventors

Göteborg, Sweden

Helene Depui